Sitaxsentan in Proteinuric Chronic Kidney Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 14, 2007

Primary Completion Date

July 7, 2009

Study Completion Date

July 7, 2009

Conditions
Chronic Kidney DiseaseProteinuriaBlood Pressure
Interventions
DRUG

Sitaxsentan

Sitaxsentan 100mg once daily oral dosing for 6 weeks

DRUG

Nifedipine

Nifedipine 30mg once daily oral dosing for 6 weeks

DRUG

Placebo tablet

Placebo tablet once daily oral dosing for 6 weeks

Trial Locations (1)

EH4 2XU

Clinical Research Centre, Western General Hospital, Edinburgh

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Encysive Pharmaceuticals

INDUSTRY

lead

University of Edinburgh

OTHER

NCT00817037 - Sitaxsentan in Proteinuric Chronic Kidney Disease | Biotech Hunter | Biotech Hunter